Business Wire

Digital Storytelling Platform ALEXANDER Launches with All-Star Cast

Share

Alexander is the digital home of original non-fiction stories from around the world. Bringing together some of the world’s most respected creative talent, Alexander’s feature stories are commissioned from acclaimed global authors and journalists and give unique access to fascinating places, cultures and people.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201124005565/en/

Using the Alexander mobile app, every original feature is presented in multiple storytelling dimensions—a commissioned written story, an audio performance and a super short film. The crafted film introduces the setting, teases the subject and sets the mood. Audiences then transition into the full story and can read, listen or move seamlessly via The Toggle, a proprietary text-to-audio functionality, between the written word and the audio performance. The convergence creates an immersive storytelling experience that meets the high expectations of discerning audiences everywhere.

Conceived and created by veteran film producer Cameron Lamb, Alexander harnesses the talents of an all-star cast of award-winning authors, A-list actors and celebrated filmmakers.

Commissioned writers include National Book Award winner Colum McCann, National Book Critics Circle Award winner Xiaolu Guo, Two-timeBooker Prize-nominated Chigozie Obioma, theoretical physicist Carlo Rovelli and National Book Critics Circle Award finalist Valeria Luiselli.

Audio performances include Academy Award nominees Helena Bonham Carter and Richard E. Grant, BAFTA and Golden Globe winner Bill Nighy, BAFTA winners Vanesa Kirby and David Tennant and SAG nominated Dan Stevens along with Daisy Edgar-Jones, ope Dìrísù and Nathalie Emmanuel among others.

Super short films come from directors including Charlotte Wales and Derek Zheng, and star the likes of Emma Corrin (debuting as Princess Diana in Netflix’s The Crown, November 2020).

“Alexander is for a global audience starved of those intimate, transporting stories that give real access to international and unexplored subjects and places,” said Alexander founder Cameron Lamb. “I wanted to create something different. To bring together three familiar mediums, entwined, working cohesively together, to deliver an immersive world. Alexander commissions brilliant writers who can find a remarkable story in a place or topic and make it feel immediate and familiar. The incredible group of actors and filmmakers we’ve brought together elevate each of these story experiences, capturing audiences from the moment they drop into the app. It’s a unique experience.”

Dugong
By J.M. Ledgard with audio performance by David Tennant and film by Russ Murphy. Traveling from the remote islands of the Torres Strait to the waters of the Arabian Gulf in search of the elusive dugong, Ledgard looks to both past and future in the race to preserve a species in the Anthropocene Age.

Killing in the Year of the Pig
By Xiaolu Guo with audio performance by Guo and film by Derek Zheng. Guo revisits the China of her childhood to unfold the story of two mass-murdering brothers and their months-long killing spree that transfixes a nation.

When the Risen Dust Settles
By Chigozie Obioma with audio performance by Ṣope Dìrísù and film by Zacker Canaperi and Drea Cooper. Nigeria’s Caritas University is ruled by the arbitrary discipline of a charismatic Catholic priest. Students are kept in dormitories without sanitation, barred from outside contact, beaten for misbehavior, and summarily expelled. When Obioma's curiosity makes him question the institution and its founder, he becomes the main target for the culture of control.

Seasick
By Jonathan Freedland with audio performance by Richard E. Grant and film by the McGloughlin Brothers. What happens when culture loses its memory and truth can’t be trusted? Jonathan Freedland, one of the world’s top political reporters, meets the people around the globe who are fighting against tech-age misinformation, Holocaust denial and the War on Facts.

In addition to new original features, Alexander also includes a curated library of historical non-fiction stories that have stood the test of time, freshly packaged in the Alexander experience.

The Alexander app will be available by subscription on iOS and downloadable on the App Store from November 24, 2020. Monthly subscription rates begin at $3.99/£3.99 following a 14-day complimentary trial. The app will be available for Android in early 2021.

Alexander App Download - https://apps.apple.com/us/app/alexander/id1529631224

--------------

About Alexander

Alexander brings global stories into accessible, captivating immediacy with high-quality original non-fiction storytelling in an audience-friendly technology experience. Every two weeks, Alexander releases an original English-language feature in its subscription application. Created by the world’s best storytellers, each feature comprises a commissioned written narrative by an award-winning author complemented and enhanced by an audio performance by A-list acting talent and a super short film of the story as interpreted by a visionary filmmaker.

For more information, visit www.alxr.com

Follow Alexander on Instagram or Twitter @alxrfeatures

Contact information

For EU media requests, please contact:
Josh Stanbury | josh@sjspr.co | +44 (0)7590 720870

For US media requests, please contact:
Charlie Windisch-Graetz | Charlie@c4global.com | +1-310-801-6910

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Servier announce updated overall survival results of exploratory TASCO1 phase II study of LONSURF ® + bevacizumab in a first-line setting for patients with unresectable mCRC non-eligible for intensive therapy16.1.2021 22:15:00 CETPress release

Servier announced today updated results from the exploratory phase II TASCO1 study evaluating LONSURF® (trifluridine/tipiracil) + bevacizumab and capecitabine + bevacizumab (C-B) in a first-line setting for patients with unresectable metastatic colorectal cancer (mCRC) who are non-eligible for intensive therapy.1 The data were announced today during an oral presentation at the 2021 ASCO Gastrointestinal Cancers Symposium (ASCO-GI). Patients with mCRC who are not eligible for chemotherapy face a large unmet need, with fewer treatment options available to them and lower survival rates. Colorectal cancer (CRC) makes up 9.7% of total global cancer cases, with almost 1.4 million new cases of CRC each year.2 In Europe, CRC is the second most common cause of death due to cancer, and those with a metastatic disease have a 5-year survival rate of just 11%.3 “For patients with metastatic colorectal cancer, those non-eligible for standard combination therapy have few options left and we are conti

H.I.G. Realty Invests in Production Studios & Content Hub in Madrid15.1.2021 09:00:00 CETPress release

H.I.G. Capital, LLC ("H.I.G."), a leading global alternative investment firm with $43 billion of equity capital under management, announced today that one of its affiliates has invested in Madrid Content City, an approximately 140,000 square meter hub with state of the art audio-visual facilities, including production studios, production & post-production technical facilities, and a university focused on media studies. H.I.G. continues to add to its sizeable portfolio of real estate assets across Europe, consisting of both equity as well as debt investments, with a particular focus on its target market of value-added small and midcap opportunities. Riccardo Dallolio, Managing Director and Head of H.I.G. Europe Realty Partners, commented: “Madrid Content City will benefit from strong secular tailwinds underpinned by the boom in content production. The state-of-the-art studios and related facilities, the exceptional multinational tenant line-up with long term leases, and its critical mas

Eurofins, the global leader in analytical testing, expands worldwide face mask testing & certification capabilities15.1.2021 07:30:00 CETPress release

Since the start of the pandemic Eurofins (Paris:ERF) has tested thousands of models of surgical and hygienic masks and provided best-in-class speed and certification for PPEs globally, enabling these critical products to get market as fast as possible. Eurofins has developed global leading testing capabilities and certification services in the North America, Europe and Asia ensuring that PPE manufacturers are able to provide the indispensable support needed in the fight against the coronavirus. As of today, Eurofins is one of the few GLP certified and ISO/IEC 17025 accredited laboratory networks to fully cover all testing requirements for surgical/medical and hygienic masks by the FDA, EU regulations and many international and country-specific directives and guidelines such as CEN, CE Marking, ISO, ASTM or OECD. Our robust portfolio for masks includes globally accepted, safety and performance testing, virucidal, bacterial filtration, particle filtration, differential pressure, biocompa

TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport ® (abobotulinumtoxinA) in five therapeutic indications15.1.2021 07:00:00 CETPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced results from new analyses of pivotal Phase III clinical trial data to assess treatment intervals over repeat cycles of Dysport® (abobotulinumtoxinA [aboBoNT-A]) in five patient populations. AbobotulinumtoxinA: Evidence for Long Duration of Response from 5 Patient Populations is being shared during the TOXINS 2021 conference, which is taking place virtually between 16-17 January 2020 and is organized by the International Neurotoxin Association.1-28 Ipsen is sharing 26 abstracts during the congress, with data including updates from the recently published surveys into the experience of patients and caregivers, data from the Phase IV ULIS-III trial, and ten abstracts focused on basic science research into neurotoxins.1-27 Spasticity is one of the most common and disabling conditions associated with many neurological conditions in adults and is characterized by velocity-dependent muscle hypertonia. Spasticity can lead to disabilit

Velodyne Lidar Commends NHTSA Plan to Update NCAP14.1.2021 21:58:00 CETPress release

Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today commended the U.S. Department of Transportation’s National Highway Traffic Safety Administration (NHTSA) plan to update to its New Car Assessment Program (NCAP). The NHTSA proposal would add four advanced driver assistance system (ADAS) capabilities to the NCAP, keeping pace with evolving safety technologies and providing much-needed information to consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005992/en/ Images show vehicle with lidar-based PAEB stopping before adult target @ 50% overlap (above) and vehicle with camera and radar-based PAEB crashing into adult target (below). (Photo: Velodyne Lidar, Inc.) NCAP is the U.S. Government’s premier consumer information program for evaluating vehicle safety performance. The NHTSA proposal to add ADAS technologies to the NCAP includes pedestrian automatic emergency braking, lane keeping support, blind spot warning and

Snow Software Recognized as a 2020 Gartner Peer Insights Customers’ Choice for Software Asset Management14.1.2021 20:39:00 CETPress release

Snow Software, the global leader in technology intelligence, today announced that the company was named a December 2020 Gartner Peer Insights Customers’ Choice for Software Asset Management (SAM) Tools. Gartner defines software asset management tools as technology that “automates many of the tasks required to maintain compliance with software licenses, thereby controlling software spending.” This is the fourth Gartner Peer Insights Customers’ Choice announcement for SAM, and Snow has earned the distinction all four times. Based solely on feedback from verified customers, Gartner Peer Insights Customers’ Choice reflects reviews and ratings published within the last 12 months. Snow received 100 reviews – the most of any vendor in the market – with an overall rating of 4.6 out of 5 as of January 12, 2021. Earlier this year, Snow was recognized as a Leader in Gartner’s 2020 Magic Quadrant for Software Asset Management Tools1 and received the highest scores in three out of four use cases in

Veristat Supported Marketing Applications for 10% of All FDA Novel Drug Approvals in 202014.1.2021 19:15:00 CETPress release

Veristat, a scientific-minded global clinical research organization (CRO), announced today that they supported the marketing applications for 10% of the 2020 US Food and Drug Administration (FDA) novel drug approvals. The FDA approved 53 novel drugs, defined by the FDA as New Molecular Entities (NMEs)i, and Veristat regulatory, statistical, and medical writing experts were integral in preparing five of these NME New Drug Applications. Veristat also prepared NDA/BLAs for three non-NME FDA approvals and one Marketing Authorization Application (MAA) that received approval in Europe. "Despite the global challenges in 2020, Veristat continued to advance its mission of helping clients achieve regulatory approval of novel medical therapies," stated Patrick Flanagan, Chief Executive Officer at Veristat. "Now, more than ever, Veristat is focused on providing expert guidance to facilitate the rapid approval for therapies that improve the lives of patients and their families around the world." Ve

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom